Metsera (NASDAQ:MTSR) Shares Gap Up – What’s Next?

Metsera Inc. (NASDAQ:MTSR)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $60.73, but opened at $68.90. Metsera shares last traded at $70.46, with a volume of 2,920,830 shares traded.

Analyst Upgrades and Downgrades

MTSR has been the subject of a number of analyst reports. Leerink Partnrs lowered Metsera from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 24th. Bank of America lifted their price target on Metsera from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, August 28th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Metsera in a research note on Wednesday, October 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Metsera in a research note on Wednesday, September 3rd. Finally, Leerink Partners reiterated a “market perform” rating and issued a $57.00 price objective (down previously from $77.00) on shares of Metsera in a report on Wednesday, September 24th. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $55.75.

Metsera Stock Performance

The company has a 50-day simple moving average of $46.57 and a two-hundred day simple moving average of $35.93. The firm has a market capitalization of $7.68 billion and a P/E ratio of -14.00.

Institutional Trading of Metsera

Several large investors have recently bought and sold shares of MTSR. Osaic Holdings Inc. boosted its position in shares of Metsera by 45.5% in the 2nd quarter. Osaic Holdings Inc. now owns 946 shares of the company’s stock worth $27,000 after purchasing an additional 296 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of Metsera by 100.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,600 shares of the company’s stock worth $46,000 after purchasing an additional 800 shares in the last quarter. Strs Ohio bought a new stake in shares of Metsera in the 1st quarter worth approximately $76,000. Virtus Investment Advisers LLC bought a new stake in shares of Metsera in the 2nd quarter worth approximately $77,000. Finally, Amalgamated Bank boosted its position in shares of Metsera by 225.2% in the 3rd quarter. Amalgamated Bank now owns 1,730 shares of the company’s stock worth $91,000 after purchasing an additional 1,198 shares in the last quarter.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.